[ad_1]
The first recurrence of malaria in the world, which affects 8.5 million people a year, has been approved in the United States in 60 years, the BBC reported Tuesday.
Malaria is characterized by multiple recurrences that have been hidden in the human liver for many years.
However, Tafenoquine, approved by the United States Food and Drug Administration (FDA), completely eliminates the parasitic triad fever virus causing recurrent malaria to the body, There is an effectiveness to avoid .
The FDA says that it is effective and that the drug is registered in the United States.
But he also points out that there could be serious side effects.
For example, patients with G6PD (glucose-6-phosphate dehydrogenase) deficiency, a condition in which red blood cells decompose sooner than their initial lifespan, can cause severe anemia and should not take tapenokine.
The FDA therefore recommends testing this deficiency in poor countries where malaria is prevalent.
People who suffer from a mental illness can have problems if they take a large amount of tapenokin.
Accordingly, the World Health Authority should carefully consider whether tapenokine is appropriate for people infected with malaria.
Scientists have described the development of Tapenoken as "a wonderful achievement".
Recurrent malaria is largely parasitic in the liver and is most common in sub-Saharan Africa.
It is particularly dangerous for children.
If you do it once, you should do it several times.
When you get malaria, you often have to be away, and when you're sick, you lose strength.
People infected with malaria become unconscious carriers.
If the parasite wakes up from the body and resumes activity, the mosquito will carry the germ to another person.
That is why it is difficult to eradicate relapsing malaria in the world.
Currently, there is a treatment for malaria called Prima Quinn, but it is a weakness that it should be prescribed more often than Thaffenokin.
r
(Seoul-Yonhap News) Lee Kyung Wook
Source link
